Do you currently have nasal polyps and are interested in non-surgical treatment options?
In this research study we want to learn more about the biologic medication called dupilumab and its potential benefit in improving the symptoms of subjects with chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD). The overall goal of this study is to better understand why patients develop nasal polyps and to determine how 8 weeks of treatment with dupilumab decreases the nasal polyps and improves sense of smell.
Dupilumab (Dupixent) is approved by the U.S. Food and Drug Administration (FDA) to treat CRSwNP. Although dupilumab is not FDA-approved specifically to treat AERD as a unique syndrome, all patients with AERD have CRSwNP an
d the dupilumab given for this study will be prescribed as an add-on maintenance treatment for inadequately controlled CRSwNP. This research study will allow us to learn how well dupilumab works to control sinus and asthma symptoms in patients with nasal polyps.
We are inviting volunteers who have a history of nasal polyps with or without AERD. The study is open to individuals who are 18-75 years of age. If you decide to join this research study, it will take you about 10 weeks to complete the study. During this time, we will ask you to make up to 4 study visits to Brigham and Women’s Hospital that will take 2-3 hours each to complete. Participants will be compensated for each study visit they complete.
For more information, please contact the AERD Center at AERD@partners.org, or contact our Research Assistant, Laura Bailey at 617-525-3824.